SCHEMBL14778457

SCHEMBL14778457

NCc1cncc(-c2ccc3c(c2)CCC(=O)N3)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 6/20 0.62
▸ CYP11B2 P19099 6/20 0.62
▸ CYP1A2 P05177 4/20 0.62
▸ PDE3B Q13370 3/20 0.61
▸ PDE3A Q14432 3/20 0.61
▸ CYP2C9 P11712 2/20 0.61
▸ TBXAS1 P24557 1/20 0.61
▸ CYP2D6 P10635 1/20 0.52
▸ CYP2B6 P20813 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ KIF11 P52732 1/20 0.51
▸ MAPT P10636 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ NPC1 O15118 1/20 0.45
▸ MMP12 P39900 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ AKT1 P31749 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21518692 0.84 CYP11B1 (0.62) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL14789821 0.80 CYP11B2 (0.57) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL31259949 0.80 CYP11B2 (0.57) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL22005295 0.80 CYP11B1 (0.67) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL1119981 0.79 CYP11B1 (0.72) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL14778454 0.79 CYP11B2 (0.61) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL14780143 0.78 CYP11B2 (0.61) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL2037485 0.77 MAOA (0.51) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
SCHEMBL1119377 0.77 CYP11B1 (1.00) CYP11B1CYP11B2CYP1A2PDE3BPDE3A
Hydrochloric Acid SCHEMBL2042591 0.76 MAOA (0.50) CYP11B1CYP11B2CYP1A2PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2755963-B1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-10-30 — — EP claimed
US-9260408-B2 Dihydroquinoline-2-one derivatives HOFFMANN-LA ROCHE INC. (US) 2016-02-16 — — US claimed
EP-2755963-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2014-07-23 — — EP claimed
CN-103814021-A New dihydroquinoline-2-one derivatives HOFFMANN LA ROCHE 2014-05-21 — — CN claimed
WO-2013037779-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-03-21 — — WO claimed
US-20130072679-A1 DIHYDROQUINOLINE-2-ONE DERIVATIVES CINCOR PHARMA, INC. 2013-03-21 — — US claimed
EP-3653618-B1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-01-08 — — EP disclosed
EP-3653618-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2020-05-20 — — EP disclosed
EP-3653618-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2020-05-20 — — EP disclosed
EP-2755963-B1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-10-30 — — EP disclosed
EP-2755963-B1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-10-30 — — EP disclosed
US-20160193212-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR AUSPEX PHARMACEUTICALS INC (US) 2016-07-07 — — US disclosed
US-9260408-B2 Dihydroquinoline-2-one derivatives HOFFMANN-LA ROCHE INC. (US) 2016-02-16 — — US disclosed
US-9260408-B2 Dihydroquinoline-2-one derivatives HOFFMANN-LA ROCHE INC. (US) 2016-02-16 — — US disclosed
EP-2755963-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2014-07-23 — — EP disclosed
CN-103814021-A New dihydroquinoline-2-one derivatives HOFFMANN LA ROCHE 2014-05-21 — — CN disclosed
WO-2013037779-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-03-21 — — WO disclosed
US-20130072679-A1 DIHYDROQUINOLINE-2-ONE DERIVATIVES CINCOR PHARMA, INC. 2013-03-21 — — US disclosed
US-20130072679-A1 DIHYDROQUINOLINE-2-ONE DERIVATIVES CINCOR PHARMA, INC. 2013-03-21 — — US disclosed
WO-2013037779-A1 NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160193212-A1 CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR P2RY12, P2RY11, P2RY2 CYP11B1 1089/4885CYP11B2 1068/4885CYP1A2 1578/4885
US-20130072679-A1 DIHYDROQUINOLINE-2-ONE DERIVATIVES CYP11B1, CYP11B2, HSD11B1 CYP11B1 1/4885CYP11B2 2/4885CYP1A2 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback